BioCentury
ARTICLE | Clinical News

Janssen completes Phase III studies of IM Risperdal

February 20, 2001 8:00 AM UTC

ALKS said that partner Janssen Pharmaceutica (Beerse, Belgium), a subsidiary of Johnson & Johnson (JNJ), completed two Phase III trials of its Risperdal risperidone sustained release depot intramuscul...